had been exposed to nitrofurantoin during the first trimester of pregnancy. Exposure to nitrofurantoin was not associated with an increased risk of birth defects in general (adjusted OR, 0.850 [95% CI,]) or specific malformations. Conclusion: First-trimester exposure to nitrofurantoin was not associated with increased risk for major birth defects as well as other specific malformations. Disclosure of Interest: None declared. Understanding the gap between evidence-based medicine and clinical practice is necessary to improve clinical outcomes in children. This study aimed to investigate the most used drugs, analyzed in defined daily doses (DDD), in the Danish paediatric wards within 1 year. Patients (or Materials) and Methods: Data were extracted from a Danish database, which contains information about the number of DDD sold to the hospital pharmacies including what is sold to the pediatric wards, hereby estimating the pediatric drug use. Two analyses were made regarding the drug consumption. A main analysis covering the 90% most used drugs where the extent of off-label use and the number of drugs having a Pediatric Investigation Plan (PIP) were explored. Nationwide, 16 hospitals were included representing both general and specialized pediatric departments. Secondly, a test sample analysis was made regarding drug use during hospital admission, covering 80% of the pediatric standard medicine assortments from 3 hospitals; results from the remaining hospitals are being prepared. Results: One hundred drugs constituted the 90% most used drugs in the pediatric wards. Divided by anatomical classification (ATC), treatment of infections (J), drugs used for alimentary tract and metabolism problems (A), and antineoplastic and immunomodulating agents (L) were most prescribed. The subgroup L has not been among the most used ATC groups before, the expenses for this subgroup constitutes 25% of the entire pediatric medicine budget. Fifteen drugs (15%) were by all indications off label, the amount of DDD used off label accounted for 9.2%. A PIP existed on 25 drugs in total. The average time from central authorization to completed PIP was 8.5 years, and 32% of the PIPs were completed by 2013. Preterm and newborns were included in 25% of the PIPs and adolescents in 64%. In the test sample 71% of the drugs were repeated when compared with the results from the main analysis. The immunomodulating agents were not included. Contrary to the main analysis, drugs aimed at the nervous system (N) were among the most used subgroups.
PP222-TheraPeuTiC
2 Institute of General Practice and Health Services Research; and 3 Institute of Clinical Chemistry, University of Zürich, Zürich, Switzerland Introduction: Daptomycin is a lipopeptide antibiotic with rapid concentration-dependent bactericidal action against Gram-positive organisms. Target daptomycin plasma concentrations have been determined in animal models for some pathogens, but data on optimal exposure in humans are still lacking. Measurement of daptomycin plasma concentration is available at our institution since 2009 and is performed regularly. The aim was to assess variability of daptomycin plasma concentrations and the main determinants influencing daptomycin exposure. Patients (or Materials) and Methods: We retrospectively collected data in patients with at least 1 determination of daptomycin plasma concentrations during the period of January 2009 to February 2012 at the University Hospital of Zurich. Samples were analyzed by LC-MS/MS. Because daptomycin is mainly eliminated by the kidneys, exposure in patients with no renal replacement therapy (nRT), intermittent RT (iRT), and continuous RT (cRT) was compared. A trough level (C min ) of at least 10 mg/L and a minimal peak level (C max ) of 50 mg/L were defined as optimal based on animal data. Results: Ninety patients were identified with a mean (SD) age of 59 (16) years and a mean body weight of 74 (21) kg with 15 (16%) patients having a BMI > 30. The mean total daptomycin dose was 448 (133) mg (range, 175-1000 mg). In 22%, daptomycin was administered every 48 hours and in 1% every 36 hours. Mean C max was 66.2 mg/L (n = 247; range, 20-236 mg/L) and mean Cmin was 16.7 mg/L (n = 116; range, 2-68 mg/L). C max and C min levels were significantly lower in cRT (52 [20] mg/L and 9.5 [7] mg/L, respectively) compared with nRT (75.6 [42] mg/L and 21.4 [16] mg/L, P < 0.0001). C min below 10 mg/L was found in 69% of cRT, in 35% of iRT, and 26% of nRT and C max was below 50 mg/L in 52% of cRT, 8% of iRT, and 27% of nRT. When controlling for plasma creatinine and albumin concentration, dose interval, administered dose/kg and BMI, cRT remained significantly associated with an increased risk of a C min level below 10 mg/L (OR = 3.1; P= 0.001) compared with nRT. There was an inverse and independent association between administered dose/ kg and C max below 50 mg/L (OR = 2.0; P = 0.003). Trough levels > 20 mg/L were mainly seen in nRT patients with renal impairment with only 2 cases of mild CK elevation. Conclusion: Daptomycin exposure is highly variable depending on renal function and renal replacement therapy used. Patients undergoing cRT had the highest proportion of low daptomycin exposure with the highest risk for possible under dosing. Disclosure of Interest: None declared. e89
Introduction: Guidelines caution prescribers and patients against chronic benzodiazepine use (BZD). Nevertheless, BZD use among nursing home residents remains high. We focused on individual residents and explored benefit and harm of chronic BZD use, willingness to try, and barriers against the discontinuation of chronic BZD use by questioning the general practitioner (GP) and the nurse. Patients (or Materials) and Methods: In this cross-sectional study, we selected nursing home residents with at least 3 months of BZD use. A resident-specific questionnaire was addressed to the GP and nurse. For every resident, the GP and nurse had to score 8 barrier statements on a 10 point Likert scale. Additionally, we collected 10 general attitudes scored by GPs and nurses. The questionnaire was based on an expert meeting and was pretested. Results: We received data for 109 chronic BZD users. GPs and nurses indicated that the BZD still had the desired effect in, respectively, 87% and 83% of the residents, and that except for dependence; there were no observed side effects in 75% and 70% of the residents. Overall, GPs had higher barriers than the nurses. Nevertheless, the willingness to stop among GPs was higher (respectively 33% vs. 21%). Both caregivers were willing to stop in 13% of the residents. The most common barriers against discontinuation was for both caregivers the fear that initial problems will come back and the preference of a pharmacologic treatment instead of a nonpharmacologic treatment. The GPs perceived the resident's motivation as a larger barrier than the nurses (median, 9 vs 7; P = 0.001) and indicated more often that discontinuation of BZDs can lead to an increase in care burden (median, 8 vs 6; P = 0.028). Of all 10 general statements, the most common attitude among both GPs and nurses was that the longer the resident takes the medication, the more difficult it is to stop (median, 8), and the resident's old age makes it difficult and unnecessary to stop. Nurses, in contrast to the GPs, indicated that there is little knowledge on alternative strategies to handle troubles when stopping BZDs (median, 7 vs 2; P < 0.001) and little scientific information available for stopping (median, 6 vs 2; P = 0.004). The scores for resident-specific barriers were higher than for general statements.
Conclusion:
The perceived effectiveness, the absence of side effects and the presence of dependence in most residents that use BZD chronically, result in a low willingness to stop. Implementation of discontinuation initiatives have to address different barriers of different parties requiring multidisciplinary evaluation of residents. Disclosure of Interest: None declared. The ICH E7 guideline for studies involving geriatric patients intends to improve the knowledge about medicines in that population. As a legislative document, it might not reflect the needs of health care professionals. This study investigated what information health care professionals, regulatory agencies, and pharmaceutical industries actually consider necessary for rational drug prescribing to older individuals. Patients (or Materials) and Methods: A 29-item questionnaire was composed, focusing on the representation of older individuals in trials, the pharmacokinetics, efficacy and safety, and the convenience of use of medicinal products. Forty-three European physicians, pharmacists, ethicists, regulators, and professionals from the pharmaceutical industry, all specialized in medication for older individuals were included. A second questionnaire was composed of 11 control items and 5 new items, based on comments. Median scores, differences between clinical and nonclinical respondents, and the consistency of responses were analyzed. Results: Thirty-seven (86%) respondents returned the initial questionnaire: 23 clinicians and 14 nonclinical professionals. The second was returned by 21 clinicians and 10 nonclinical professionals (31/37 [84%]). There were no significant differences between respondents regarding 10 control items. Information about 32 (94%) of the 34 items was considered necessary. Information about age-related differences in adverse events, locomotor effects, drug-disease interactions, dosing instructions, and information about the proportion of included 65+ patients was considered necessary by most respondents. The clinicians considered information significantly more important than did the nonclinical respondents about the inclusion of 75+, time until benefit in older people, anticholinergic effects, drug-disease interactions, and the convenience of use. Conclusion: This study reveals that items considered necessary are currently not included in the ICH E7 guideline or its supplement, the Q&A document; namely, information about effects on the locomotor system, drug-disease interactions, and dosing instructions. Also, clinicians' and nonclinicians' opinions differed significantly in 15% of the items. Therefore, all stakeholders should collaborate to improve the availability of information for the rational prescribing of medicines to older individuals. 
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